FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3009271488> ?p ?o ?g. }

• W3009271488 endingPage "710" @default.
• W3009271488 startingPage "701" @default.
• W3009271488 abstract "Abstract Background The PURE-01 study (NCT02736266) evaluated the use of pembrolizumab before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC). Objective To evaluate the ability of molecular signatures to predict the pathological complete response (CR: ypT0N0) and progression-free survival (PFS) after pembrolizumab and RC. Design, setting, and participants We analyzed the expression data from patients with T2–4aN0M0 MIBC enrolled in the PURE-01 study (N = 84) and from patients of a retrospective multicenter cohort treated with cisplatin-based neoadjuvant chemotherapy (NAC; N = 140). Intervention Neoadjuvant pembrolizumab or NAC and RC. Outcome measurements and statistical analysis Immune signatures and molecular subtyping (The Cancer Genome Atlas, consensus model, and genomic subtyping classifier [GSC]) were evaluated in relation to CR and PFS. Multivariable logistic regression analyses for CR were used, adjusting for gender and clinical T stage. Results and limitations The Immune190 signature was significant for CR on multivariable logistic regression analyses (p =  0.02) in PURE-01, but not in the NAC cohort (p =  0.7). Hallmark signatures for interferon gamma (IFNγ; p =  0.004) and IFNα response (p =  0.006) were also associated with CR for PURE-01, but not for NAC (IFNγ: p =  0.9 and IFNα: p =  0.8). In PURE-01, 93% of patients with the highest Immune190 scores (>1st quartile) had 2-yr PFS versus 79% of those with lower scores; no difference was observed in NAC patients, as well as for the other hallmarks in both groups. The neuroendocrine-like subtype had the worst 2-yr PFS in all three subtyping models (33%) and the GSC claudin-low subtype had the best, with no recurrences in 2 yr. Basal subtypes (across classifications) with higher Immune190 scores showed 100% 2-yr PFS after pembrolizumab therapy (p = 0.04, compared with basal-Immune190 low). Statistical analyses are limited by the small number of events and short follow-up. Conclusions Higher RNA-based immune signature scores were significantly associated with CR and numerically improved PFS outcomes after pembrolizumab, but not after NAC. These data emphasize that RNA profiling is a potential tool for personalizing neoadjuvant therapy selection. Patient summary We used gene expression profiling to evaluate the association between immune gene expression and response to neoadjuvant immunotherapy, compared with standard chemotherapy, in patients with muscle-invasive bladder cancer (MIBC). We found a significant association between immune gene expression and response to pembrolizumab, but not chemotherapy. We conclude that gene expression profiling has the potential to guide personalized neoadjuvant therapy in MIBC." @default.
• W3009271488 created "2020-03-13" @default.
• W3009271488 creator A5000621664 @default.
• W3009271488 creator A5004542037 @default.
• W3009271488 creator A5006746061 @default.
• W3009271488 creator A5012466586 @default.
• W3009271488 creator A5014582211 @default.
• W3009271488 creator A5022442590 @default.
• W3009271488 creator A5023266580 @default.
• W3009271488 creator A5023363049 @default.
• W3009271488 creator A5029125718 @default.
• W3009271488 creator A5031550729 @default.
• W3009271488 creator A5036320874 @default.
• W3009271488 creator A5038974730 @default.
• W3009271488 creator A5039363062 @default.
• W3009271488 creator A5049044895 @default.
• W3009271488 creator A5050196540 @default.
• W3009271488 creator A5054660525 @default.
• W3009271488 creator A5058849092 @default.
• W3009271488 creator A5059157811 @default.
• W3009271488 creator A5061623935 @default.
• W3009271488 creator A5078216208 @default.
• W3009271488 creator A5080250383 @default.
• W3009271488 creator A5081296401 @default.
• W3009271488 creator A5083331837 @default.
• W3009271488 creator A5086507632 @default.
• W3009271488 creator A5088559019 @default.
• W3009271488 creator A5090061046 @default.
• W3009271488 date "2020-06-01" @default.
• W3009271488 modified "2023-10-17" @default.
• W3009271488 title "Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer" @default.
• W3009271488 cites W1893588230 @default.
• W3009271488 cites W2035062922 @default.
• W3009271488 cites W2131178190 @default.
• W3009271488 cites W2214074259 @default.
• W3009271488 cites W2289712604 @default.
• W3009271488 cites W2432541865 @default.
• W3009271488 cites W2462649057 @default.
• W3009271488 cites W2604535399 @default.
• W3009271488 cites W2734446741 @default.
• W3009271488 cites W2763670669 @default.
• W3009271488 cites W2802899563 @default.
• W3009271488 cites W2806413184 @default.
• W3009271488 cites W2807188318 @default.
• W3009271488 cites W2890545119 @default.
• W3009271488 cites W2897581535 @default.
• W3009271488 cites W2913857335 @default.
• W3009271488 cites W2922520449 @default.
• W3009271488 cites W2933974970 @default.
• W3009271488 cites W2962566270 @default.
• W3009271488 cites W2975497362 @default.
• W3009271488 cites W2981145485 @default.
• W3009271488 cites W2987436342 @default.
• W3009271488 cites W2988581606 @default.
• W3009271488 cites W2996950697 @default.
• W3009271488 doi "https://doi.org/10.1016/j.eururo.2020.02.028" @default.
• W3009271488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32165065" @default.
• W3009271488 hasPublicationYear "2020" @default.
• W3009271488 type Work @default.
• W3009271488 sameAs 3009271488 @default.
• W3009271488 citedByCount "112" @default.
• W3009271488 countsByYear W30092714882020 @default.
• W3009271488 countsByYear W30092714882021 @default.
• W3009271488 countsByYear W30092714882022 @default.
• W3009271488 countsByYear W30092714882023 @default.
• W3009271488 crossrefType "journal-article" @default.
• W3009271488 hasAuthorship W3009271488A5000621664 @default.
• W3009271488 hasAuthorship W3009271488A5004542037 @default.
• W3009271488 hasAuthorship W3009271488A5006746061 @default.
• W3009271488 hasAuthorship W3009271488A5012466586 @default.
• W3009271488 hasAuthorship W3009271488A5014582211 @default.
• W3009271488 hasAuthorship W3009271488A5022442590 @default.
• W3009271488 hasAuthorship W3009271488A5023266580 @default.
• W3009271488 hasAuthorship W3009271488A5023363049 @default.
• W3009271488 hasAuthorship W3009271488A5029125718 @default.
• W3009271488 hasAuthorship W3009271488A5031550729 @default.
• W3009271488 hasAuthorship W3009271488A5036320874 @default.
• W3009271488 hasAuthorship W3009271488A5038974730 @default.
• W3009271488 hasAuthorship W3009271488A5039363062 @default.
• W3009271488 hasAuthorship W3009271488A5049044895 @default.
• W3009271488 hasAuthorship W3009271488A5050196540 @default.
• W3009271488 hasAuthorship W3009271488A5054660525 @default.
• W3009271488 hasAuthorship W3009271488A5058849092 @default.
• W3009271488 hasAuthorship W3009271488A5059157811 @default.
• W3009271488 hasAuthorship W3009271488A5061623935 @default.
• W3009271488 hasAuthorship W3009271488A5078216208 @default.
• W3009271488 hasAuthorship W3009271488A5080250383 @default.
• W3009271488 hasAuthorship W3009271488A5081296401 @default.
• W3009271488 hasAuthorship W3009271488A5083331837 @default.
• W3009271488 hasAuthorship W3009271488A5086507632 @default.
• W3009271488 hasAuthorship W3009271488A5088559019 @default.
• W3009271488 hasAuthorship W3009271488A5090061046 @default.
• W3009271488 hasConcept C121332964 @default.
• W3009271488 hasConcept C121608353 @default.
• W3009271488 hasConcept C126322002 @default.
• W3009271488 hasConcept C142724271 @default.
• W3009271488 hasConcept C143998085 @default.
• W3009271488 hasConcept C153400128 @default.

• next